Trial Profile
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 29 Nov 2015 New trial record